Related Experiment Video

Updated: Apr 6, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

602

Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose

Andreas Hanslik1, Erwin Kitzmüller1, Ulrich S Tran2

  • 1Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Austria;

Blood
|August 5, 2015
PubMed

Insights

Monitoring unfractionated heparin (UFH) in children requires careful consideration of dose and age. Anti-Xa, aPTT, and ACT assays showed dose-effect relationships but poor agreement, with age significantly impacting UFH

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Unfractionated heparin (UFH) monitoring is critical for preventing anticoagulation complications in children.
  • Optimal UFH monitoring parameters in pediatric populations remain poorly defined.

Purpose of the Study:

  • To examine the relationship between UFH dose and anticoagulant effect using anti-Xa, aPTT, and ACT in children.
  • To identify factors influencing UFH efficacy, assess assay agreement, and correlate UFH effect with clinical outcomes.

Main Methods:

  • A randomized controlled trial (HEARTCAT) compared high-dose vs. low-dose UFH during pediatric cardiac catheterization.
  • Blood samples were analyzed for anti-Xa, aPTT, and ACT at multiple time points post-UFH administration.

Main Results:

  • All assays demonstrated a clear UFH dose-effect relationship, with UFH dose, age, and baseline antithrombin influencing anti-Xa levels.
  • UFH effects were diminished in infants compared to older children, particularly at lower UFH doses.
  • Agreement between anti-Xa, aPTT, and ACT was poor; aPTT was often uninterpretable for UFH monitoring.

Conclusions:

  • While UFH assays reflect a dose-effect relationship, their poor agreement complicates monitoring in children.
  • Age significantly influences UFH anticoagulant effect in a dose-dependent manner, necessitating age-specific monitoring strategies.
  • Current monitoring assays, especially aPTT, have limitations in pediatric UFH management.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.2K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341